EUVIMEDEUVIMED entdecken
Crossref

In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant

Huilin Zhang iD, Yiwei Zhang, Haili Hu, Wenqin Yang, Xue Xia, Lei Lei, Ruyi Lin, Jiamei Li, Yuan Li, Huile Gao iD

Small · 2023-08 · 19 (33)

DOI: 10.1002/smll.202301041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 20.04.2023. Verfasst von Huilin Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Higher Education Discipline Innovation Project, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor vaccine is a promising cancer treatment modality, however, the convenient antigens loading in vivo and efficient delivery of vaccines to lymph nodes (LNs) still remain a formidable challenge. Herein, an in situ nanovaccine strategy targeting LNs to induce powerful antitumor immune responses by converting the primary tumor into whole‐cell antigens and then delivering these antigens and nanoadjuvants simultaneously to LNs is proposed. The in situ nanovaccine is based on a hydrogel system, which loaded with doxorubicin (DOX) and nanoadjuvant CpG‐P‐ss‐M. The gel system exhibits ROS‐responsive release of DOX and CpG‐P‐ss‐M, generating abundant in situ storage of whole‐cell tumor antigens. CpG‐P‐ss‐M adsorbs tumor antigens through the positive surface charge and achieves charge reversal, forming small‐sized and negatively charged tumor vaccines in situ, which are then primed to LNs. Eventually, the tumor vaccine promotes antigens uptake by dendritic cells (DCs), maturation of DCs, and proliferation of T cells. Moreover, the vaccine combined with anti‐CTLA4 antibody and losartan inhibits tumor growth by 50%, significantly increasing the percentage of splenic cytotoxic T cells (CTLs), and generating tumor‐specific immune responses. Overall, the treatment effectively inhibits primary tumor growth and induces tumor‐specific immune response. This study provides a scalable strategy for in situ tumor vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsHumansAnimalsMiceT-Lymphocytes, CytotoxicImmunotherapyDoxorubicinAntigens, NeoplasmLymph NodesDendritic CellsMice, Inbred C57BL

Stichwörter der Autor:innen

CTLA4antigen deliveryin situ vaccineslosartanlymph node targetstumor vaccines

Substanzen

Cancer VaccinesDoxorubicinAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
  • Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.

ORCID-Profile: Huilin Zhang, Huile Gao

Förderung

  • Higher Education Discipline Innovation Project
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zhang, H., Zhang, Y., Hu, H., Yang, W., Xia, X., Lei, L., Lin, R., Li, J., Li, Y., & Gao, H. (2023). In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant. Small, 19(33). https://doi.org/10.1002/smll.202301041

Vancouver

Zhang H, Zhang Y, Hu H, Yang W, Xia X, Lei L, et al. In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant. Small. 2023;19(33). doi:10.1002/smll.202301041

BibTeX
@article{Zhang2023,
  author = {Zhang, Huilin and Zhang, Yiwei and Hu, Haili and Yang, Wenqin and Xia, Xue and Lei, Lei and Lin, Ruyi and Li, Jiamei and Li, Yuan and Gao, Huile},
  title = {In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant},
  journal = {Small},
  year = {2023},
  volume = {19},
  number = {33},
  doi = {10.1002/smll.202301041}
}
Kostenlos starten →